James Komorowski, MS, CNS, vice president of scientific and regulatory affairs at Nutrition 21, presented the results of three preclinical studies on Nutrition 21’s patented amylopectin and chromium combination ingredient, Velositol, at the ISSN (International Society of Sports Nutrition) conference on June 24th in Phoenix.
Bionano Genomics and Genoptix today announced an exclusive agreement to codevelop diagnostic assays for selected hematologic oncology indications. Bionano will contribute its knowledge of genome structure analysis and its Saphyr system, which is designed to accurately visualize the structure of a genome with a simple DNA sample, isolated directly from cancer cells. The platform can …
1315 Capital, LLC, an expansion and growth equity firm that invests in commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies, announced today the continued expansion of its senior investment team with the addition of Matthew Q. Reber as a Partner. Mr. Reber joins Founding Partners, Adele C. Oliva and Michael Koby, and brings deep …
Chromium picolinate has long been known for its positive effects on glucose metabolism when it comes to weight management. However, more than 35 clinical studies on humans have been completed on a brand of chromium picolinate called Chromax, a dietary supplement ingredient developed by Nutrition 21.
Onkos Surgical announced the completion of the company’s first ELEOS Limb Salvage System procedure using uDesign Patient Solutions. uDesign delivers an interactive experience, enabling a personalized planning approach for each patient. The first surgery was conducted by Steven Gitelis, M.D., of Rush University Medical Center in Chicago.
Onkos Surgical, Inc., a specialty medtech company focused on surgical oncology, today announced that it closed a $17.6 million round in Series B funding. Canaan Partners led the funding round and existing investors 1315 Capital and 3D Systems also participated. Onkos will use the new funding to expand its sales, marketing, and R&D platforms to …
Onkos Surgical, an innovative surgical oncology company, has announced today it has partnered with PatientIQ, a healthcare data, research and analytics technology company, to launch a platform for the collection of clinical data for surgical oncology patients.
An experienced management team, led by Joseph M. Limber, in partnership with Ampersand Capital Partners and 1315 Capital, has completed the acquisition of Genoptix, Inc. from Novartis. The financial terms of the transaction are not being disclosed. Headquartered in Carlsbad, California, Genoptix is a recognized leader in its field, and is one of the largest …
An experienced management group led by Joseph M. Limber, in partnership with Ampersand Capital Partners and 1315 Capital, has entered into a definitive agreement to acquire the commercial laboratory of Genoptix, Inc., a Novartis company that specializes in oncology diagnostics and informatics services. This transaction is expected to close in the first quarter of 2017 …
Encore Dermatology Inc., a privately held dermatology company that specializes in developing and commercializing novel prescription products for improving skin health, announced today the availability of TridesilonTM (desonide) Cream, 0.05% in a 60g tube. TridesilonTM Cream, 0.05% is a low-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
1315 Capital, LLC, an expansion and growth equity firm that invests in commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies today announced the recent expansion of its team with the addition of Edward Chan.
Onkos Surgical has announced today it has received clearance from the U.S. Food and Drug Administration to market the ELEOS™ Limb Salvage System to treat patients with significant bone loss due to cancer, trauma, or previous surgical procedures.